H.C. Wainwright Maintains Buy rating on BioLife (BLFS) Stock
On May 27, H.C. Wainwright reaffirmed its Buy rating on BioLife Solutions, Inc. (NASDAQ:BLFS) while keeping the price target the same at $30.
Biolife Solutions Inc (BLFS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Casdin Capital Eli Casdin | 8,707,165 | $198,871,649 | 16.25% | |
| 2. | Royce & Associates Chuck Royce | 860,744 | $19,659,393 | +11% | 0.21% |
| 3. | Millennium Management Israel Englander | 388,504 | $8,873,431 | -67% | 0% |
| 4. | Ranger Investment Management Conrad Doenges (Cio) | 336,840 | $7,693,426 | -1% | 0.55% |
| 5. | 154,300 | $3,524,212 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.19 | 927,165 | $10,374,976.35 | 8,557,165 | 2023-10-19 | Filing | |
| $13.20 | 58,465 | $771,743.85 | 7,630,000 | 2023-08-09 | Filing | |
| $21.86 | 24,973 | $545,789.91 | 150,000 | 2023-05-22 | Filing | |
| $22.55 | 50,000 | $1,127,430.00 | 125,027 | 2023-05-19 | Filing | |
| $21.76 | 30,000 | $652,692.00 | 75,027 | 2023-05-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.23 | 711 | $15,805.53 | 78,721 | 2025-06-16 | Filing | |
| $23.80 | 1,000,000 | $23,800,000.00 | 7,707,165 | 2025-06-10 | Filing | |
| $23.70 | 362 | $8,579.40 | 134,922 | 2025-06-10 | Filing | |
| $23.70 | 637 | $15,096.90 | 353,118 | 2025-06-10 | Filing | |
| $23.70 | 1,042 | $24,695.40 | 186,685 | 2025-06-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,472,493 | $124,991,740 | 0% | |
| 2. | 3,551,054 | $81,106,073 | 0.02% | |
| 3. | 2,804,140 | $64,046,557 | 0% | |
| 4. | 522,378 | $36,926,901 | 0.01% | |
| 5. | 1,533,122 | $35,016,506 | 0.2% |
News See All
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions First Quarter 2025 Shareholder and Analyst Conference Call.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Q3 2024 Shareholder and Analyst Conference Call.
BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2
Conestoga Capital Advisors, an asset management company, released its “Micro-Cap Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Organ Transplant and Diagnosis Stocks To Buy Now
In the dynamic landscape of healthcare, the importance of organ transplantation cannot be overstated.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2024 Earnings Call Transcript
BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.19, expectations were $-0.26.
Corporate Insiders Are Selling These 10 Small-Cap Stocks
In this article, we will take a detailed look at Corporate Insiders Are Selling These 10 Small-Cap Stocks. For a quick overview of such stocks, read our article Corporate Insiders Are Selling These...
BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2024 Earnings Call Transcript
BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.36. BioLife Solutions, Inc.
BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles
Conestoga Capital Advisors, an asset management company, released its “Micro Cap Strategy” third-quarter 2023 investor letter. A copy of the same can be downloaded here.
BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst Conference Call.